Pharmaceutical composition for prevention or treatment of fibrotic diseases and application thereof

A technology of fibrotic diseases and compositions, applied in the field of medicine, can solve problems such as organ function decline and organ fibrosis, and achieve good prevention and treatment effects

Inactive Publication Date: 2017-08-08
REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
View PDF3 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If this repair response is excessive, strong, and out of control, it will cause organ fibrosis and lead to organ function decline

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for prevention or treatment of fibrotic diseases and application thereof
  • Pharmaceutical composition for prevention or treatment of fibrotic diseases and application thereof
  • Pharmaceutical composition for prevention or treatment of fibrotic diseases and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Embodiment 1: the preparation of nintedanib capsule

[0062] Nintedanib capsules were prepared according to the following method and the proportioning of materials in Table 1:

[0063] Table 1: Ratio of nintedanib capsules

[0064]

[0065] Heat the prescribed amount of medium-chain triglycerides, mixed fatty acid glycerides, and soybean lecithin to 40-50°C to melt, add the prescribed amount of nintedanib ethanesulfonate that has passed through a 0.8mm sieve, mix well, and press the In a quality machine (rotating speed 20000r / min), make 3-5 times, each time for 2 minutes, until the contents are in a completely uniform state, and the capsule liquid is obtained, which is filled into the capsule shell by pressing or dripping method, and is prepared into a soft capsule, that is, have to.

Embodiment 2

[0066] Embodiment 2: the physicochemical property of nintedanib capsule

[0067] According to two kinds of prescriptions of embodiment 1, prepare 200 soft capsules respectively, observe the appearance of soft capsules, check the difference in loading (the difference in loading must not exceed 7.5%), measure the dissolution rate (paddle method (two appendix XC of Chinese Pharmacopoeia version in 2015) The second method)), determination of content (respectively determine 0 days and accelerated January 40 ℃, RH75% content).

[0068] Liquid phase detection method: use octadecylsilane bonded silica gel as filler; use 0.1% trifluoroacetic acid as mobile phase A, acetonitrile as mobile phase B, perform gradient elution according to Table 2, and the flow rate is 1.0 mL per minute; The detection wavelength is 387nm, and the column temperature is 35°C.

[0069] Table 2: Gradient ratio composition of liquid phase eluent

[0070]

[0071] Content determination method: take 20 capsule...

Embodiment 3

[0086] Example 3: Inhibitory effect of nintedanib ethanesulfonate on renal fibrosis in rats

[0087] 50 male SD rats were randomly divided into 5 groups according to the principle of similar body weight, 10 rats in each group, namely the sham operation group, the model control group, the low dose group of the test product, the medium dose group of the test product and the high dose of the test product Group. Experimental animals were anesthetized on day 0 (D0) and laparotomy was performed in the middle, and the left kidney was separated. The ureter was separated at the lower pole of the left kidney, and unilateral ureteral ligation (UUO) was performed. In the sham operation group, only laparotomy and separation of the left kidney were performed.

[0088] Dosing began on the next day (D1) after the operation, the animals in the sham operation group (group 1) were not treated, the animals in the model control group (group 2) were given vehicle, and the low dose group of the te...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of nintedanib, its salt and solvate in preparation of drugs for prevention or treatment of fibrotic diseases and a pharmaceutical composition for prevention or treatment of fibrotic diseases. The pharmaceutical composition comprises an active component and excipients, wherein the active component is selected from one or more of nintedanib, its salt and solvate. The nintedanib preparation provided by the invention can achieve treatment or prevention of fibrotic diseases on VEGF, PDGF and FGF angiogenesis receptors, and can provide an effective drug concentration, thus reaching a good control effect.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for preventing or treating fibrosis diseases and its application. Background technique [0002] Nintedanib, namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, molecular formula C31H33N5O4, the compound structure is as follows: [0003] [0004] Nintedanib is a novel angiogenesis inhibitor that can simultaneously act on three key receptor families involved in angiogenesis: vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) ) and fibroblast growth factor receptor (FGFR). Nintedanib has been approved by the FDA and EMA for the treatment of idiopathic pulmonary fibrosis (IPF), and has also been approved by the EMA for use in combination with docetaxel after first-line chemotherapy for locally advanced adenocar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P1/16A61P13/12A61P9/00A61P1/18A61P15/00A61P13/08A61P15/14A61P1/00A61P11/00A61P27/02
CPCA61K31/496Y02A50/30
Inventor 郭树华张佳春
Owner REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap